FELIX GELLER: Open Payments
NPI 1902073216 · TOMS RIVER, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,633 in 170 payments from 19 companies in 2025. Trend: 2023 $2,297 · 2024 $3,484 · 2025 $3,633
Food & beverage: $3,524Education: $109
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $785 |
| Alkermes, Inc. | 20 | $557 |
| Otsuka America Pharmaceutical, Inc. | 35 | $529 |
| Axsome Therapeutics, Inc. | 19 | $347 |
| Teva Pharmaceuticals USA, Inc. | 15 | $306 |
| Janssen Pharmaceuticals, Inc | 8 | $252 |
| Braeburn Inc. | 6 | $207 |
| Tris Pharma Inc | 11 | $173 |
| Neurocrine BioSciences, Inc. | 8 | $172 |
| Vanda Pharmaceuticals Inc. | 4 | $64 |
Products named: CAPLYTA, REXULTI, LYBALVI, Auvelity, ARISTADA, BRIXADI, SPRAVATO, INGREZZA.
Industry payments across NJ — which companies pay providers there.
